As far as I am aware the only news is what was in previous announcement. Ie phase 1 announcement 8/04/20 to asx. deal to conduct trial with 40 healthy subjects, run in Australia outside hospital system and controlled by Parexel. Dosing expected to start second half of this year and results expected by April next year. parexel were apparently also involved with rce in earlier discussions about FDA requirements so hopefully the results apply there also.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)